For the Inventor, By the Inventor

Enter inventor name

Berlin, Germany

Heribert Schmitt-Willich

USPTO Granted Patents = 52 (Patent Applications = 13)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 20)

Average Co-Inventor Count = 5.9

ph-index = 12

Forward Citations = 412(Granted Patents)

Forward Citations (Not Self Cited) = 370(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

38 out of 1,384

Schering Aktiengesellschaft

Piramal Imaging Sa

Life Molecular Imaging Sa

Schering Aktiengessellschaft

Life Molecular Imaging Limited

8. 1 out of 192

Bayer Schering Pharma Ag

Schering Aktiengeseuschaft

10. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2022

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Gamma-Carboline Compounds

Tau Protein Aggregates

Radiolabeled Amino Acids

Macrocyclic Metal Complexes

DTPA Monoamides

Cascade Polymer Complexes

Polyrotaxane Derivatives

Iron(III) Complexes

Diagnostic Imaging

Pharmaceutical Agents

Complexing Agents

Contrast Agents

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11306089 - Gamma-carboline compounds for the detection of Tau aggregates (2022-04-19),

2. 10865207 - Compounds for imaging Tau protein aggregates (2020-12-15),

3. 10835624 - Compounds for imaging Tau protein aggregates (2020-11-17),

4. 10662193 - Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins (2020-05-26),

5. 9308282 - [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation (2016-04-12),

6. 9238631 - Radiolabeled amino acids for diagnostic imaging (2016-01-19),

7. 9017645 - Homoglutamic acid derivatives (2015-04-28),

8. 9000037 - Precursors of glutamate derivatives (2015-04-07),

9. 7618957 - Perfluoroalkyl-containing complexes, process for their production as well as their use (2009-11-17),

10. 7211241 - Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes (2007-05-01),

11. 7208139 - Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them (2007-04-24),

12. 7164016 - Macrocyclic metal complexes and their use for the production of conjugates with biomolecules (2007-01-16),

13. 7074387 - DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production (2006-07-11),

14. 6861043 - Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes (2005-03-01),

15. 6855309 - Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them (2005-02-15),

Title: The Innovative Contributions of Heribert Schmitt-Willich

Introduction: Heribert Schmitt-Willich, based in Berlin, Germany, has made significant strides in the field of biomedical innovations, particularly focusing on the detection of Tau aggregates associated with neurodegenerative disorders. With an impressive portfolio of 52 patents, his work stands out for its potential impact on understanding and visualizing diseases like Alzheimer’s.

Latest Patents: Among his latest innovations are two noteworthy patents. The first is titled "Gamma-carboline compounds for the detection of Tau aggregates," which presents novel compounds capable of selectively detecting Tau aggregates linked to disorders such as Alzheimer’s disease through Positron Emission Tomography (PET) Imaging. The second patent, "Compounds for imaging Tau protein aggregates," also emphasizes the development of unique compounds that facilitate the selective detection of abnormalities associated with Tau aggregates, further enhancing the capabilities of PET imaging.

Career Highlights: Throughout his career, Schmitt-Willich has been associated with prominent organizations that have influenced his innovative journey. Notably, he has worked with Schering Aktiengesellschaft, a leading pharmaceutical company known for its focus on medical advancements. Additionally, he has contributed to the work at Piramal Imaging, where his research has greatly impacted the field of imaging and diagnostics.

Collaborations: Collaboration has played a crucial role in Schmitt-Willich’s accomplishments. He has worked alongside esteemed colleagues such as Johannes Platzek and Heinz Gries, contributing to various projects and research initiatives that have furthered the understanding and treatment of neurodegenerative diseases.

Conclusion: Heribert Schmitt-Willich’s contributions to the field of biomedical research, particularly through his patents focused on Tau detection, illustrate the positive impact of innovation in healthcare. His collaborations and career experiences reflect a commitment to advancing medical imaging technologies, potentially paving the way for better diagnostic tools and therapeutic strategies in the fight against Alzheimer’s and related conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…